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Cytotoxic agents have unequivocal activity in non-small cell lung
cancer. Currently available agents have demonstrated the abil-
ity to prolong life and improve quality of life in advanced
disease, and to increase the rate of cure when used in stage I and
II disease in the adjuvant setting and as part of chemoradio-
therapy in stage III disease. These agents have served as the core
regimen to which agents effecting newly discovered molecular
targets are added. However, there is little question that there is
much room for improvement. A number of new agents have
been identified that either derive from older drugs or affect their
targets in novel ways. In particular, tubulin has been an attrac-
tive target since the dawn of medical oncology. A number of new
antitubulin agents are currently in development. Epothilones
are novel agents that bind to the same site as taxanes, yet are
structurally distinct. Xyotax and abraxane are agents in which
paclitaxel is delivered in a novel fashion that may both reduce
toxicity and enhance activity. ABT 751 is an agent that targets
the colchicine site of tubulin. Another approach is to enhance the
activity of currently available agents by targeting detoxification
and resistance pathways. TLK-286 is a novel agent that may
enhance the activity of previously available agents by inhibiting
GST-pi, a detoxifying mechanism that may be of particular
relevance to platinum agents. It has also demonstrated some
single-agent cytotoxic activity.
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Recently there has been a great deal of emphasis placed onthe development of new anticancer agents specifically
targeted against angiogenisis, signal transduction modulators,
and other novel targets. These agents have been generically
referred to as “biologics” and have been viewed as potentially
revolutionizing the field. However, it has become increas-
ingly apparent that such agents may very well possess sub-
stantial toxicity and will achieve their highest levels of
activity when combined with the traditional and somewhat
demeaned cytotoxic drugs. Implicit within much of this
discussion is the belief that cytotoxic agents are neither
rational nor likely to produce any substantial advances. This
approach fails to recognize the substantial improvements in
the lives of patients with cancer, including cures and effective
adjuvant therapy made with currently available drugs, and
neglects the potential future contributions of the many agents
now in development. At the 6th Annual Targeted Therapies
for the Treatment of Lung Cancer Conference, there were a
number of presentations focusing on new cytotoxic agents.
NEW ANTIMICROTUBULIN AGENTS
One class of agents has been particularly effective in a
broad range of neoplastic diseases, and numerous new agents
broadly contained within this class but possessing unique
properties are now in development. Although many new
approaches offer hope, there are currently seven approved
antimicrotubule agents, one or more of which play a signif-
icant role in most major solid and hematologic malignancies.
Antimicrotubule agents have been generally thought to act
through prevention of assembly or disassembly of mitotic
tubulin. Although this effect occurs, it tends to be seen
primarily at higher (stoichiometric) concentrations. At lower,
more clinically achievable drug concentrations, the antimi-
crotubule agents act more though interference with microtu-
bule dynamics. Additionally, it has been increasingly recog-
nized that antimicrotubule agents have pro-apoptotic effects
mediated through phosphorylation (and hence inactivation) of
the bcl-2 protooncogene. Furthermore, at relatively low con-
centrations, the taxanes display anti-angiogenic properties
and anti-invasive properties, probably relating to inhibition of
tubulin necessary for cell motility. The increasing awareness
of numerous subsets of tubulin and the tissue-specific nature
of tubulin offer fertile opportunities for targeting of these
agents against specific tumors. A number of mechanisms of
resistance to antimicrotubule agents have been described,
including the multidrug resistance gene, alteration in tubulin
dynamics, and mutations or polymorphisms in beta tubulin.
Epothilones
The epothilones are a new class of antimicrotubule
agents in advanced clinical trials. Epothilones share a mech-
anism of action similar to paclitaxel, in that they enhance
microtubule assembly and seem to share a binding site.1,2
Epothilone B, however, has demonstrated activity in mdr
expressing cell lines and in in vivo models with considerable
resistance to paclitaxel.3 Several epothilones are currently in
clinical trials, including ixabepilone (BMS 247550, Bristol
Myers Squibb, Princeton, NJ), patupilone (EPO 906, Novar-
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tis, Basel, Switzerland), and KOS-862 (Kosan, Hayward,
CA). The first two are considered epothilone B, the last is an
epothilone D. Ixabepilone and patupilone are structurally
very similar but have demonstrated markedly different tox-
icity profiles. Neurotoxicity and myelosuppression are dose-
limiting for ixabepilone, whereas diarrhea is dose-limiting for
patupilone.4,5 The Kos-862 compound has a toxicity profile
similar to ixabepilone.
There is considerable clinical experience with these
agents in non-small cell lung cancer (NSCLC). Ixabepilone
has been extensively evaluated for the second line treatment
of NSCLC and has demonstrated activity at least comparable
to docetaxel. A randomized phase II trial enrolling more than
150 patients was conducted in the United States and Europe.
Patients received either a 6 mg/m2 daily  5 dose or 40
mg/m2 (decreased to 32 mg/m2) q 21 days dose. The study
required prior platinum therapy. More than 50% of patients in
both arms had also previously received taxanes. Clear activity
was demonstrated (13% on the q21 day arm and 10% on the
daily  5), including responses among patients who were
refractory to docetaxel (90 days since therapy).6 A non-
cremophor containing formulation of the drug and an oral
version are currently undergoing Phase I evaluation. KOS-
862 has reported activity in second-line therapy for NSCLC
in a multi-institutional trial.7 This study enrolled 55 patients,
and 35 were evaluable. One partial response was seen, as well
as some patients with prolonged disease stability.
New Taxanes
Paclitaxel and docetaxel have unequivocal activity in
NSCLC. It is therefore logical to attempt to improve on this
activity with manipulations of the taxane molecule. A number
of strategies have been used to reduce toxicity by eliminating
the cremophor vehicle necessary for the administration and/or
enhance the activity of taxanes.8 A particularly fruitful strat-
egy has been to bind paclitaxel to a polymer or to embed in
a nanoparticle of albumin to enhance tumor delivery or
decrease toxicity. Paclitaxel poliglumex (Xyotax) binds pac-
litaxel to a polymer, resulting in enhanced tumor uptake and
decreased toxicity.9 The drug has demonstrated activity in
NSCLC, and three large randomized trials have recently been
reported: Selective Targeting for Efficacy in Lung Cancer,
Lower Adverse Reactions (STELLAR) 2, 3, and 4. STEL-
LAR 2 was a study comparing paclitaxel poliglumex with
docetaxel for second-line therapy of NSCLC.10 STELLAR 3
and 4 tested the agent as first-line therapy. In STELLAR 3,
the agent was combined with carboplatin and compared with
the standard carboplatin/paclitaxel regimen among patients
with compromised performance status.11 STELLAR 4 com-
pared the single agent with an investigator’s choice of either
single-agent vinorelbine or gemcitabine as first-line therapy
among patients with performance status 2.11,12 None of the
three studies demonstrated superiority for the paclitaxel poli-
glumex-containing arms. However, all demonstrated that the
agent had at least a comparable level of activity, with less
toxicity in terms of neuropathy, alopecia, and myalgias.
Intriguingly, a preplanned subgroup analysis of STELLAR 3
and 4 demonstrated significant survival improvements among
women patients, particularly those with potentially high lev-
els of circulating estrogen (i.e., premenopausal). This finding
is biologically plausible as a high estrogenic environment
induces cathepsin B, which is necessary for intracellular
cleavage and consequent activation of paclitaxel from the
poliglumex backbone. As a result of this analysis, a new
phase III trial evaluating the agent versus paclitaxel among
chemotherapy-naı¨ve women with advanced NSCLC and
compromised performance status has been initiated.
ABI-007 (Abraxane, Abraxis) is paclitaxel bound to
nanoparticles of albumin. The agent was developed to reduce
the toxicities of paclitaxel by obviating the need for a cre-
mophor solvent and to improve the chemotherapeutic effect
by taking advantage of endogenous albumin pathways.13,14 In
a phase III comparison study conducted among patients with
breast cancer, overall toxicity was comparable for the ABI-
007 (260 mg/m2) and paclitaxel (175 mg/m2) groups, despite
the higher dose of ABI-007.15 Grade 4 neutropenia occurred
less frequently in the ABI-007 group, did not seem to be
cumulative, and was typically asymptomatic and transient.
Grade 3 sensory neuropathy occurred more frequently in the
ABI-007 group but improved more rapidly with ABI-007. In
this study, ABI-007 demonstrated greater efficacy than pac-
litaxel, resulting in a higher response rate and longer progres-
sion-free survival. In addition, overall survival was increased
for patients who had previously received treatment for met-
astatic breast cancer. As a result of these findings, ABI-007
was approved for treatment of breast cancer. The experience
with ABI-007 in NSCLC is more limited. ABI-007 has been
evaluated as a single agent for advanced NSCLC and dem-
onstrated significant activity, with a response rate of 35% of
34 evaluable patients.16,17
ABT-751
ABT-751 is a novel antitubulin agent that binds to the
colchicine site. It demonstrated in vitro efficacy against lung
cancer cell lines. Neurotoxicity (particularly ileus) and my-
elosuppression were dose-limiting in phase I studies. Preclin-
ical evidence indicates that the colchicine family of antitu-
bulin agents exerts an antivascular effect as well as an
antimitotoic effect.18,19 There is relatively limited clinical
experience with this agent, with only one phase I trial in
hematologic malignancies reported.20 The agent was evalu-
ated in 35 taxane-refractory patients at a dose of 200 mg qd
for 21 days, followed by a 7-day rest period.21 Patients were
heavily pretreated; virtually all had also received platinum
therapy and many EGFR inhibitors. No grade 3 or 4 hema-
tologic toxicities were noted. The most common toxicities
were anorexia and constipation (45%). There were 31 pa-
tients evaluable for survival and response. Median progres-
sion-free survival was 3.1 months; median overall survival
was 10.4 months. One partial response was seen with several
minor response and prolonged stable disease patients.
TLK-286
TLK286 (initially TER286) is a novel rationally de-
signed prodrug activated by glutathione S-transferase P1-1
(GST P1-1) to its active forms.22,23 GST P1-1 is elevated in
tumors relative to normal tissues, thereby providing tumor
selectivity. TLK286 is metabolized by GST P1-1 to two
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fragments. One of the fragments has structural similarities to
alkylating agents but seems to result in cell death through
activation of the stress response pathway. In addition, this
agent is synergistic with other agents, including platinums (J.
Keck, personal communication, August 2003). Thus, TLK-
286 has potential for single-agent activity and to potentiate
other agents.
Phase I studies of TLK 286 have demonstrated that the
agent is well tolerated with a dose-limiting toxicity of hema-
turia and dysuria.24 These symptoms are reversible and will
not recur with dose reduction. Antitumor activity in NSCLC
(and other solid tumors) was demonstrated in the phase I
study based on prolonged disease stability. Phase II studies in
NSCLC confirmed this activity with documented responses.25
A phase III trial comparing TLK-286 with gefitinib as third-
line therapy for NSCLC has completed enrollment, but re-
sults have not yet been reported. An ongoing trial of TLK286
in combination with docetaxel in second-line therapy has
demonstrated surprisingly high response rates. Given the
potential for synergy, TLK-286 was combined with cisplatin
for first-line therapy with NSCLC.26 More recently, TLK-286
has been combined with carboplatin and paclitaxel in first-
line therapy.27 This combination was well tolerated with a
surprisingly high response rate, although the numbers were
small and only a limited number of institutions participated.
Other Novel Cytotoxics
A considerable number of other novel cytotoxics are
currently in development. As stated above agents targeting
tubulin are of clear efficacy. Recently, drugs targeting other
parts of the mitotic spindle apparatus have entered develop-
ment. The mitotic spindle apparatus is complex, consisting of
several proteins, including aurora kinases, survivin and others
that are needed to coordinate and regulate mitosis to assure
correct segregation of chromosomes and cell division.28
Overexpression and abnormalities in these proteins have been
associated with malignancy, and inhibitors have significant
potential as anticancer agents. Failure of correct chromosome
segregation can result in aneuploidy, polyploid cells, and
mitotic cell death. At least three classes of agents, including
aurora kinase inhibitors, kinesin spindle protein inhibitors,
and anti-survivin molecules, are now in development. Aurora
kinases are a highly conserved molecules with at least three
classes described, Aurora A, B, and C.29 Aurora A is involved
with mitosis, and Aurora B with chromosomal congression
and cytokinesis. Aurora C is found in germ cells and is of
uncertain significance. Several inhibitors are under develop-
ment.30 MK-0457 is a non-selective inhibitor, AZD-1152 a
selective inhibitor of aurora B. Recently presented phase I
studies demonstrate that the drugs are active and that neutro-
penia is the dose-limiting toxicity.31,32
Kinesin spindle proteins are responsible for spindle
pole separation during mitosis. The kinesin motor proteins
are ATPases that produce mechanical force along tubulin.33
This provides for the physical movement of tubulin and
structures bound to tubulin (e.g., chromosomes). In addition
to mitosis, kinesin spindle proteins are important for neuronal
transport, cilial and flagellar assembly, organelle positioning,
etc. Numerous kinesins have been identified. These proteins
are most abundant in proliferating tissues, overexpressed in
cancer, and not expressed in postmitotic tissues (particularly
neurons). Kinesin spindle protein inhibitors have now entered
trials.34,35
CONCLUSIONS
The approval of ABI-007 and the completion of several
large randomized trials of other “cytotoxic” drugs demon-
strate continuing interest by industry, investigators, and pa-
tients in this approach. The targets of tubulin and DNA
remain important for the treatment of cancer. Within this
same broad category of agents, drugs targeting other compo-
nents of the mitotic spindle are demonstrating promising
levels of activity in early trials. In addition, drugs such as
TLK-286 demonstrate the potential for agents with mecha-
nisms that potentiate other cytotoxic agents. It is also clear
that, as with the targeted agents, the optimal use of these
drugs will require better identification of populations likely to
benefit.
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